# A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps

Source: https://onco.cc/trials/nct07589634/  
OnCo record `nct07589634` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of JNJ-79635322, Tocilizumab in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.

## Summary

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07589634 by Janssen Research & Development, LLC, with 230 participants planned, started 2026-06-30 and due to reach its primary completion in 2027-12-31. Interventions recorded: Ramantamig, Tocilizumab, Placebo. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07589634
- Phase: 2
- Setting: 79635322MMY2002: Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 230

## Sources

- ClinicalTrials.gov NCT07589634: https://clinicaltrials.gov/study/NCT07589634

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [JNJ-79635322](https://onco.cc/drugs/jnj-79635322/), [Tocilizumab](https://onco.cc/drugs/tocilizumab/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct07589634.json